Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma

Chin Med J (Engl). 2023 Mar 20;136(6):732-734. doi: 10.1097/CM9.0000000000002570.

Authors

Ruiying Fu¹, Yuanzheng Liang¹, Liqiang Wei¹, Xindi Liu¹, Yingshi Piao^{2

3}, Liang Wang^{1

3}

Affiliations

¹ Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
² Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
³ Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Dexamethasone / therapeutic use
Etoposide / therapeutic use
Gemcitabine
Humans
Lymphoma, Extranodal NK-T-Cell* / drug therapy
Lymphoma, Extranodal NK-T-Cell* / pathology
Lymphoma, T-Cell* / pathology
Neoplasm Staging
Treatment Outcome

Substances

Gemcitabine
pegaspargase
Etoposide
Dexamethasone